The National Institutes of Health (NIH)


Research (R, P, D and U Announcements)

Title (Activity Code) Deadline Announcement Number
Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool September 15, 2020 NOT-OD-20-152
Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Research Project – Cooperative Agreements) September 15, 2020 RFA-OD-20-022
Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Research Demonstration-Cooperative Agreements) September 18, 2020 RFA-OD-20-018
Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Research Demonstration – Cooperative Agreements) September 18, 2020 RFA-OD-20-017
Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R42 Small Business Technology Transfer (STTR) Grant – Phase II only) September 18, 2020 RFA-OD-20-021
Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Small Business Innovation Research (SBIR) Grant – Phase II only) September 18, 2020 RFA-OD-20-020
Metastasis Research Network (U54 Specialized Center-Cooperative Agreement) September 28, 2020; May 28, 2021 RFA-CA-20-029
Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Research Project Grant) September 30, 2020 RFA-OD-20-016
Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Exploratory/Developmental Grants Phase II) October 30, 2020 RFA-CA-20-044
Characterizing causal mechanisms to prevent dental fear and anxiety (R01 Research Project Grant) November 10, 2020 RFA-DE-21-001
Disseminating and Implementing Patient-Centered Outcomes Research (PCOR) Evidence into Practice through Interoperable Clinical Decision Support (R18 Research Demonstration and Disseminations Projects) January 25, May 25, September 25 PA-20-074
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Research Project Grant) February 5, June 5, October 5 PAR-20-276
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Exploratory/Developmental Research Grant) February 16, June 16, October 16 PAR-20-277
Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 Exploratory/Developmental Research Grant) February 16, June 16, October 16 PA-18-874
Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 Research Project Grant) February 5, June 5, October 5 PAR-18-875
NIH Research Project Grant (R01 Research Grant) February 5, June 5, October 5 PA-20-185
NIH Exploratory/Developmental Research Grant Program (R21 Research Grant) February 16, June 16, October 16 PA-20-195
Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities Varies NOT-MD-20-025
Innovative Research in Cancer Nanotechnology (IRCN) (R01 Research Project Grant) Varies PAR-20-284
Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions Varies NOT-OD-20-106
Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches Varies NOT-DE-20-006
Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 Rolling NOT-MH-20-053
Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Research Grant) February 16, June 16, October 16 PAR-20-232
Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Research Grant) February 5, June 5, October 5 PAR-20-233
Notice of Special Interest (NOSI): Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network November 2, 2020 NOT-DE-20-023
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR November 2, 2020 NOT-DE-20-022
Notice of Special Interest: Health Services Research on Minority Health and Health Disparities (R01 Research Project Grant) February 5, June 5, October 5 NOT-MD-20-011
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Research Project Grant) February 5, June 5, October 5 PAR-20-155
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Research Project Grant) February 5, June 5, October 5 PAR-20-131
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Exploratory/Developmental Research Grant) September 29, 2020 RFA-CA-20-017
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Exploratory/Developmental Grants Phase II) September 29, 2020 RFA-CA-20-018
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Exploratory/Developmental Research Grant) September 29, 2020 RFA-CA-20-019
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Exploratory/Developmental Grants Phase II) September 29, 2020 RFA-CA-20-020
National Dental Practice-Based Research Network Infrastructure Access (X01 Resource Access Award) September 1 PAR-20-073
Biomedical Data Repository (U24 Resource-Related Research Projects – Cooperative Agreements) January 25, September 25 PAR-20-089
Research Answers to National Cancer Institute’s (NCI) Provocative Questions (R21 Exploratory/Developmental Research Grant) November 17, 2020 RFA-CA-20-005
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Exploratory/Developmental Research Grant) November 18, 2020 RFA-CA-20-007
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01Research Project – Cooperative Agreements) November 18, 2020 RFA-CA-20-008
National Cancer Institute Program Project Applications (P01 Research Program Projects) January 25, May 25, September 25 PAR-20-077
Improving oral health and reducing disparities in adolescents (R01) February 5, June 5, October 5 PAR-20-058
Improving oral health and reducing disparities in adolescents (R21) February 16, June 16, October 16 PAR-20-059
NIDCR Small Grant Program for New Investigators (R03) February 16, June 16, October 16 PAR-19-370
Collaborative Program Grant for Multidisciplinary Teams (RM1) January 25, 2020; May 25, 2020 PAR-17-340
Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) September 25 PAR-19-259
Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42) January 5, April 5, September 5 PA-19-021
Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44) January 5, April 5, September 5 PA-19-022
Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42) January 5, April 5, September 5 PA-19-075
Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44) January 5, April 5, September 5 PA-19-076
NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03) February 16, June 16, October 16 PAR-19-145
Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01) February 5, June 5, October 5 PAR-19-292
Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21) February 16, June 16, October 16 PAR-19-293
Basic and Translational Oral Health Research Related to HIV/AIDS (R01/ R21) January 7, May 7, September 7 PA-18-699, PA-18-695
Precision Imaging of Oral Lesions (R01/R21) R01: February 5, June 5, October 5 / R21: February 16, June 16, October 16 PAR-18-787 (R01)/PAR-18-788 (R21)
NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) February 6, June 6, and October 6 PAR-18-547
HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional) October 21, 2020; February 21, 2021 RFA-NS-19-018
Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01/R21) R01: February 5, June 5, October 5 / R21: February 16, June 16, October 16 PA-18-874
Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01) R01: February 5, June 5, October 5 PA-18-876
Clinical Research to Improve the Oral Health of Older Adults (R21) October 16, February 16, June 16 PAR-19-240
Clinical Research to Improve the Oral Health of Older Adults (R01) October 5, February 5, June 5 PAR-19-239

Training (K Announcements)

Title (Activity Code) Deadline Announcement Number
Mentored Research Scientist Development Award (K01 Training Grant) February 12, June 12, October 12 PA-20-190
Mentored Quantitative Research Development Award (K25 Training Grant) March 12, July 12, November 12 PA-20-199
Mentored Clinical Scientist Research Career Development Award (K08) February 12, June 12, October 12 PA-19-117
Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Career Enhancement Award) October 12, February 12, June 12 PAR-19-238
NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01) February 12, June 12, October 12 PAR-18-359
Midcareer Investigator Award in Patient-Oriented Research (K24) February 12, June 12, October 12 PA-19-122
Mentored Patient-Oriented Research Career Development Award (K23) February 12, June 12, October 12 PA-19-119
NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) February 12, June 12, October 12 PAR-19-144
NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00 F99/K00 Individual Predoctoral to Postdoctoral Transition Award) February 12, June 12, October 12 PAR-20-069

Research (R, P, D and U Announcements)

Title: Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool
Announcement Number: NOT-OD-20-152
Deadline: September 15, 2020
Purpose: NIH is issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this NOSI is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Award: Requests are expected not to exceed $250,000 in total direct costs. Total direct costs requested may not exceed the direct cost amount of the current year’s award. Maximum direct costs are exclusive of consortium/contractual Facilities and Administrative (F&A) costs. Requests are limited to one year of support.
Eligibility & Guidelines: Here
Announcement Expires:  September 16, 2020


Title: Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Research Project – Cooperative Agreements)
Announcement Number: RFA-OD-20-022
Deadline: September 15, 2020
Purpose: NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this FOA is to solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Award: The total budget for direct costs for the project period of up to 3 years may not exceed $750,000. No more than $500,000 may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires:  September 16, 2020


Title: Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Research Demonstration-Cooperative Agreements)
Announcement Number: RFA-OD-20-018
Deadline: September 18, 2020
Purpose: The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. NIH intends to commit $10 million in total costs over a two-year period. NIH anticipates funding 5 awards.
Eligibility & Guidelines: Here
Announcement Expires:  September 19, 2020


Title: Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Research Demonstration – Cooperative Agreements)
Announcement Number: RFA-OD-20-017
Deadline: September 18, 2020
Purpose: The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees.
Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19. These devices are expected to actively detect VOCs from skin and oral cavities of COVID-19 patients, without being invasive, or affecting the integrity of the skin and oral cavity. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology or Gas Chromatography (GC). Therefore, this program is called SCENT, which stands for Screening for COVID-19 by Electronic-Nose Technology. This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings.
This FOA requires multidisciplinary collaborations to ensure project success. Disciplines may include: biomedical engineers, material scientists, biosensing experts, software engineers, chemists, dentists, clinicians, virologists, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry.
The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. NIH intends to commit $10 million in total costs over a two-year period. NIH anticipates funding 5 awards.
Eligibility & Guidelines: Here
Announcement Expires:  September 19, 2020


Title: Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R42 Small Business Technology Transfer (STTR) Grant – Phase II only)
Announcement Number: RFA-OD-20-021
Deadline: September 18, 2020
Purpose: The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
The goal of this RFA is to solicit Fast-Track STTR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses.
The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $256,580 for Phase I awards and $1,710,531 for Phase II awards. NIH has received a waiver from SBA, as authorized by statute, to exceed these total award amount hard caps for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Navigate to the “Program Descriptions and Research Topics” document, Appendix A or the current “SBA approved topics list for budget waivers”.
Eligibility & Guidelines: Here
Announcement Expires: September 19, 2020


Title: Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Small Business Innovation Research (SBIR) Grant – Phase II only)
Announcement Number: RFA-OD-20-020
Deadline: September 18, 2020
Purpose: The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
The goal of this RFA is to solicit Direct to Phase II SBIR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses.
The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $1,710,531 for Phase II awards. NIH has received a waiver from SBA, as authorized by statute, to exceed these total award amount hard caps for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Navigate to the “Program Descriptions and Research Topics” document, Appendix A or the current “SBA approved topics list for budget waivers”.
Eligibility & Guidelines: Here
Announcement Expires: September 19, 2020


Title: Metastasis Research Network (U54 Specialized Center-Cooperative Agreement)
Announcement Number: RFA-CA-20-029
Deadline: September 28, 2020; May 28, 2021
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to develop a comprehensive and cohesive understanding of cancer metastasis. Towards this goal, the National Cancer Institute (NCI) will support several U54 Specialized Centers that together will form the Metastasis Research Network (MetNet). Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multi-disciplinary basic research projects. The projects should use integrative approaches to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. Overarching themes should encompass the interplay between at least two central elements in the metastatic process such as early dissemination, cellular and/or physical microenvironment crosstalk, dormancy, or mechanisms of responses by metastatic cells to therapies.
Research proposed by MetNet Centers is expected to advance our understanding towards a more comprehensive appreciation of metastasis as a whole body, systems-level problem.
Award: Application budgets may not exceed $1.2M per year in direct costs.
Eligibility & Guidelines: Here
Announcement Expires:  May 29, 2021


Title: Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Research Project Grant)
Announcement Number: RFA-OD-20-016
Deadline: September 30, 2020
Purpose: NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate.
The funding for this initiative is provided form the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. NIH intends to commit $7M in FY 2021 to fund 6-8 awards.
Eligibility & Guidelines: Here
Announcement Expires: October 01, 2020


Title: Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Exploratory/Developmental Grants Phase II)
Announcement Number: RFA-CA-20-044
Deadline: October 30, 2020
Purpose: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation J, the development of New Enabling Cancer Technologies.
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new cancer data visualization methods and tools that have the potential to make data aligned with the Cancer Moonshot more explorable and interpretable by the broader cancer research community. This FOA supports the development of new, full-featured data visualization tools for investigator-specified, Moonshot-aligned use cases that enable a broader community of users to explore and gain insights from data emerging from or aligned with one or more of the Cancer Moonshot areas.
Award: Application budgets must reflect the actual needs of the proposed project but must not exceed $250,000 per year in direct costs.
Eligibility & Guidelines: Here
Announcement Expires:  October 31, 2020


Title: Characterizing causal mechanisms to prevent dental fear and anxiety (R01 Research Project Grant)
Announcement Number: RFA-DE-21-001
Deadline: November 10, 2020
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to test causal mechanisms underlying the etiology or prevention of dental fear, anxiety, or phobia. Novel insights about the causal forces that initiate, shape, or impede the development of dental fear will be essential for informing evidence-based interventions to prevent dental fear.
Award: Direct costs are limited to $300,000 in any single year.
Eligibility & Guidelines: Here
Announcement Expires:  November 26, 2020


Title: Disseminating and Implementing Patient-Centered Outcomes Research (PCOR) Evidence into Practice through Interoperable Clinical Decision Support (R18 Research Demonstration and Disseminations Projects)
Announcement Number: PA-20-074
Deadline: January 25, May 25, September 25
Purpose: This Funding Opportunity Announcement invites R18 grant applications that disseminate and implement patient-centered outcomes research evidence in clinical practice by scaling computer-based, interoperable clinical decision support.
Award: The total costs (direct and indirect) for a project awarded under this FOA will not exceed $1,000,000 in any given year and $3 million for the entire project period.
Eligibility & Guidelines: Here
Announcement Expires:  January 26, 2022


Title: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Research Project Grant)
Announcement Number: PAR-20-276
Deadline: February 5, June 5, October 5
Purpose: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.
Award: The budget is limited to $350,000 direct costs per year and should reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2022


Title: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Exploratory/Developmental Research Grant)
Announcement Number: PAR-20-277
Deadline: February 16, June 16, October 16
Purpose: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.
Award: Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2022


Title: Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 Exploratory/Developmental Research Grant)
Announcement Number: PA-18-874
Deadline: February 16, June 16, October 16
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory/developmental, investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.
Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 direct costs may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 Research Project Grant)
Announcement Number: PAR-18-875
Deadline: February 5, June 5, October 5
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: NIH Research Project Grant (R01 Research Grant)
Announcement Number: PA-20-185
Deadline: February 5, June 5, October 5
Purpose: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: May 08, 2023


Title: NIH Exploratory/Developmental Research Grant Program (R21 Research Grant)
Announcement Number: PA-20-195
Deadline: February 16, June 16, October 16
Purpose: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires: May 08, 2023


Title: Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities
Announcement Number: NOT-MD-20-025
Deadline: Varies
Purpose: The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.
Award: Varies
Eligibility & Guidelines: Here
Announcement Expires: May 08, 2023


Title: Innovative Research in Cancer Nanotechnology (IRCN) (R01 Research Project Grant)
Announcement Number: PAR-20-284
Deadline: Varies
Purpose: This Funding Opportunity Announcement (FOA) entitled “Innovative Research in Cancer Nanotechnology (IRCN)” encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.
Award: Application budgets are limited to $450K in direct costs per year and need to reflect the actual needs of the proposed project.
Eligibility & Guidelines:

Title: Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions
Announcement Number: NOT-OD-20-106
Deadline: Varies
Purpose: This Notice encourages translational behavioral intervention research, integrated with basic behavioral and social science, aimed at creating, refining, and testing novel interventions focused on the initiation, cessation, or maintenance of behaviors associated with improved health or disease mitigation.
The behavioral, emotional, cognitive, and/or social targets for the intervention/s being developed and tested in response to this NOSI, should be based on insights from basic science about mechanisms that underlie health-related behavior change. Interventions may target the individual (e.g., cognitive or psychological processes), the immediate social environment (e.g., dyadic or family relationships), and/or broader social, organizational or environmental systems (e.g., worksites, schools, healthcare delivery, or neighborhood features).
Eligibility & Guidelines:
Here
Announcement Expires: September 26, 2022


Title: Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches
Announcement Number: NOT-DE-20-006
Deadline: Varies
Purpose: The volume, dimension, and complexity of biomedical and behavioral research data are expanding rapidly, requiring bioinformatic, computational, and data science approaches to manage and analyze the data, address new questions, and obtain deeper insight from the data. This Notice of Special Interest (NOSI) calls for research and research training projects that focus on dental, oral, and craniofacial biology and diseases using bioinformatic, computational, and data science approaches.
Eligibility & Guidelines: Here
Announcement Expires: August 08, 2023


Title: Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19
Announcement Number: NOT-MH-20-053
Deadline: Rolling
Purpose: This Notice of Special Interest (NOSI) highlights interest in research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. While the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact.
Eligibility & Guidelines: Here
Announcement Expires: December 30, 2020


Title: Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Research Grant)
Announcement Number: PAR-20-232
Deadline: February 16, June 16, October 16
Purpose: This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Award: Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year.
Eligibility & Guidelines: Here
Announcement Expires: May 08, 2023


Title: Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Research Grant)
Announcement Number: PAR-20-233
Deadline: February 5, June 5, October 5
Purpose: This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: May 08, 2023


Title: Notice of Special Interest (NOSI): Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network
Announcement Number: NOT-DE-20-023
Deadline: November 2, 2020
Purpose: National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) conducted in the National Dental Practice-Based Research Network (PBRN). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices, prevent SARS-CoV-2 transmission, and improve detection and diagnosis of COVID-19. Successful X01 applicants will be given access to the National Dental PBRN infrastructure to support an individual project. Successful applications will utilize the resources of and be funded through the National Dental PBRN Administrative and Resource Center and/or National Coordinating Center for study planning and implementation.
Award: Requests are limited to a one year project duration.
Eligibility & Guidelines: Here
Announcement Expires:  November 3, 2020


Title: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR
Announcement Number: NOT-DE-20-022
Deadline: November 2, 2020
Purpose: National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices. These topics include prevention of SARS-COV-2 transmission and improvements in the detection and diagnosis of COVID-19; as well as acquisition of a more robust understanding of SARS-CoV-2 pathogenesis. Further, topics addressing influence and interaction of sex (a biological variable) and gender (a social construct), race and ethnicity, and those addressing questions about risk, prevention, and health outcomes are also of interest.
Award: Requests are expected not to exceed $150,000 in total direct costs; strong compelling justification is needed to exceed this cap.
Eligibility & Guidelines: Here
Announcement Expires:  November 3, 2020


Title: Notice of Special Interest: Health Services Research on Minority Health and Health Disparities (R01 Research Project Grant)
Announcement Number: NOT-MD-20-011
Deadline: February 5, June 5, October 5
Purpose: The purpose of this Notice of Special Interest is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.
Eligibility & Guidelines: Here
Announcement Expires:  September 08, 2022


Title: Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Research Project Grant)
Announcement Number: PAR-20-155
Deadline: February 5, June 5, October 5
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  September 08, 2022


Title: Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Research Project Grant)
Announcement Number: PAR-20-131
Deadline: February 5, June 5, October 5
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients’ benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.
Award: Application budgets are limited to $450,000 direct costs per year.
Eligibility & Guidelines: Here
Announcement Expires:  May 8, 2023


Title: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Exploratory/Developmental Research Grant)
Announcement Number: RFA-CA-20-017
Deadline: September 29, 2020
Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Award: Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.
Eligibility & Guidelines: Here
Announcement Expires:  September 30, 2020


Title: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Exploratory/Developmental Grants Phase II)
Announcement Number: RFA-CA-20-018
Deadline: September 29, 2020
Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Award: Direct costs are limited to $300,000 per year. Application budgets need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  September 30, 2020


Title: Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Exploratory/Developmental Research Grant)
Announcement Number: RFA-CA-20-019
Deadline: September 29, 2020
Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Award: Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year. Application budgets need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  September 30, 2020


Title: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Exploratory/Developmental Grants Phase II)
Announcement Number: RFA-CA-20-020
Deadline: September 29, 2020
Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Award: Direct costs are limited to $300,000 per year.
Eligibility & Guidelines: Here
Announcement Expires:  September 30, 2020


Title: National Dental Practice-Based Research Network Infrastructure Access (X01 Resource Access Award)
Announcement Number: PAR-20-073
Deadline: September 1, 2020; September 1, 2021; and September 1, 2022
Purpose: The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple clinical studies. This Funding Opportunity Announcement (FOA) is seeking applications for small developmental/exploratory, feasibility (pilot), and/or survey studies of practitioners and/or patients to be conducted in the National Dental PBRN. Successful X01 applicants will be given access to the National Dental PBRN infrastructure to support an individual project. Successful applications will utilize the resources of and be funded through the National Dental PBRN Administrative and Resource Center and/or National Coordinating Center for study planning and implementation. This FOA seeks projects up to two years in length. The main goals of the dental PBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice. This FOA encourages applications proposing research studies that align with the goals of the dental PBRN.
Award: There is no budget associated with X01 Resource Access Awards.
Eligibility & Guidelines: Here
Announcement Expires:  September 2, 2022


Title: Biomedical Data Repository (U24 Resource-Related Research Projects – Cooperative Agreements)
Announcement Number: PAR-20-089
Deadline: September 25, 2020; January 25, 2021; September 24, 2021; January 25, 2022; September 26, 2022; January 25, 2023
Purpose: This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  May 09, 2023


Title: Research Answers to National Cancer Institute’s (NCI) Provocative Questions (R21 Exploratory/Developmental Research Grant)
Announcement Number: RFA-CA-20-005
Deadline: November 17, 2020
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI’s priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these “Provocative Questions” (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.
Award: Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Application budgets should reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: November 18, 2020


Title: Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Exploratory/Developmental Research Grant)
Announcement Number: RFA-CA-20-007
Deadline: November 18, 2020
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.
Award: Direct costs are limited to $275,000 over a two year period. No more than $200,000 may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires: November 19, 2020


Title: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Research Project – Cooperative Agreements)
Announcement Number: RFA-CA-20-008
Deadline: November 18, 2020
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.
Award: Budgets are limited to $300,000 Direct Costs (excluding consortium F&A) per year.
Eligibility & Guidelines: Here
Announcement Expires: November 19, 2020


Title: National Cancer Institute Program Project Applications (P01 Research Program Projects)
Announcement Number: PAR-20-077
Deadline: January 25, May 25, September 25
Purpose: With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: May 8, 2023


Title: Improving oral health and reducing disparities in adolescents (R01)
Announcement Number: PAR-20-058
Deadline: February 5, June 5, October 5
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2023


Title: Improving oral health and reducing disparities in adolescents (R21)
Announcement Number: PAR-20-059
Deadline: February 16, June 16, October 16
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.
Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 direct costs may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2023


Title: NIDCR Small Grant Program for New Investigators (R03)
Announcement Number: PAR-19-370
Deadline: February 16, June 16, October 16
Purpose: The NIDCR Small Grant Program for New Investigators (R03) supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.
Award: A budget for direct costs of up to $200,000 may be requested. Application budgets should not exceed $100,000 in direct costs in either year.
Eligibility & Guidelines: Here
Announcement Expires:  September 8, 2022


Title: NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
Announcement Number: PAR-19-259
Deadline: September 25, 2020; September 25, 2021
Purpose: This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDA’s mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.
Award: Application budgets for direct costs cannot exceed $10,000,000 for the entire 5 year project period including no cost extensions, but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2022


Title: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42)
Announcement Number: PA-19-021
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delivery, effectiveness of clinical decision-making and outcomes of treatments associated with dental, oral and craniofacial (DOC) tissues. Among the areas of interest of this FOA are development of digital imaging and image processing capabilities for dental radiology, and the integration of 3-dimensional (3D) additive manufacturing (e.g., 3D printing) with imaging tools. This FOA also supports efforts to develop, integrate, adapt, optimize, and validate new and existing dental materials designed for additive manufacturing approaches in the repair, replacement and restoration of DOC tissues.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Eligibility & Guidelines: Here
Announcement Expires:  September 6, 2021


Title: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44)
Announcement Number: PA-19-022
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delivery, effectiveness of clinical decision-making and outcomes of treatments associated with dental, oral and craniofacial (DOC) tissues. Among the areas of interest of this FOA are development of digital imaging and image processing capabilities for dental radiology, and the integration of 3-dimensional (3D) additive manufacturing (e.g., 3D printing) with imaging tools. This FOA also supports efforts to develop, integrate, adapt, optimize, and validate new and existing dental materials designed for additive manufacturing approaches in the repair, replacement and restoration of DOC tissues.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project
Eligibility & Guidelines: Here
Announcement Expires:  September 6, 2021


Title: Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42)
Announcement Number: PA-19-075
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Eligibility & Guidelines: Here
Announcement Expires: January 6, 2022


Title: Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44)
Announcement Number: PA-19-076
Deadline: September 5, January 5, April 5
Purpose: This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Award: According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Eligibility & Guidelines: Here
Announcement Expires: January 6, 2022


Title: NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03)
Announcement Number: PAR-19-145
Deadline: February 16, June 16, October 16
Purpose: The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.
Award: A budget for direct costs of up to $100,000 per year, with a maximum of $200,000 direct costs over two years, may be requested.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01)
Announcement Number: PAR-19-292
Deadline: February 5, June 5, October 5
Purpose: This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic investigation of the interplay of genes/gene networks and environmental factors in dental, oral, craniofacial (DOC), and other diseases and conditions.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2022


Title: Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21)
Announcement Number: PAR-19-293
Deadline: February 16, June 16, October 16
Purpose: This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS , and NICHD solicit applications to develop novel and robust experimental systems that offer approaches complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.
Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2022


Title: HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)
Announcement Number: RFA-NS-19-018
Deadline: October 21, 2020; February 21, 2021
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device and is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.
This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices’ existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data.
For more information, see https://braininitiative.nih.gov/resources/brain_ppp/index.htm, https://commonfund.nih.gov/sparc/newmarkets, and https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  February 23, 2021


Title: Basic and Translational Oral Health Research Related to HIV/AIDS (R01/ R21)
Announcement Number: PA-18-699, PA-18-695
Deadline: May 7, September 7, January 7
Purpose: This funding opportunity announcement (FOA) encourages innovative basic and translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires:  January 8, 2021


Title: NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01)
Announcement Number: PAR-18-359
Deadline: February 12, June 12, October 12
Purpose: The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-321).
Award: Award budgets are composed of salary and other program-related expenses, as described below. NIDCR will contribute up to $ 100,000 per year toward the salary of the career award recipient. Further guidance on budgeting for career development salaries is provided in the SF424 (R&R) Application Guide. NIDCR will contribute $25,000 per year toward the research development costs of the award recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities. Salary for mentors, secretarial and administrative assistants, etc. is not allowed.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2021


Title: Precision Imaging of Oral Lesions (R01/R21)
Announcement Number: PAR-18-787 (R01)/PAR-18-788 (R21)
Deadline: R01: February 5, June 5, October 5 / R21: February 16, June 16, October 16
Purpose: The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.
Award: Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3)
Announcement Number: PAR-18-547
Deadline: October 6, 2020
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit the Program Director/Principal Investigator to finalize the study team and will support activities to develop: the final clinical protocol; the Clinical Investigator’s Brochure (or equivalent), if needed; the data management system and other tools for data collection and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UG3 planning phase is not designed for pre-clinical studies with animals, the collection of preliminary data on the efficacy of the intervention (such as pilot testing), or the collection of observational data from humans to support the rationale for a clinical trial. Evaluation of the potential subject population to determine individuals’ eligibility for participation in the future UH3 trial is allowed in the UG3 phase but not required. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial.
Award: Application budgets are limited to less than $400,000 in direct costs for the UG3 phase; Application budgets are not limited for the UH3 phase, but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2021


Title: Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01/R21)
Announcement Number: PA-18-874
Deadline: R01: February 5, June 5, October 5 / R21: February 16, June 16, October 16
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory/developmental, investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.
Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 direct costs may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01)
Announcement Number: PA-18-876
Deadline: February 5, June 5, October 5
Purpose: The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other ‘-omic’ sciences, biotechnology, and bioinformatics.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01)
Announcement Number: PA-18-876
Deadline: February 5, June 5, October 5
Purpose: The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other ‘-omic’ sciences, biotechnology, and bioinformatics.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Eligibility & Guidelines: Here
Announcement Expires: September 8, 2021


Title: Clinical Research to Improve the Oral Health of Older Adults (R21)
Announcement Number: PAR-19-240
Deadline: February 16, June 16, October 16
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.
Award: The combined budget for direct costs for the two-year project period may not exceed $275,000 direct costs. No more than $200,000 direct costs may be requested in any single year.
Eligibility & Guidelines: Here
Announcement Expires:  September 8, 2022


Title: Clinical Research to Improve the Oral Health of Older Adults (R01)
Announcement Number: PAR-19-239
Deadline: February 5, June 5, October 5
AIDS Dates: May 7, 2020; September 7, 2020; January 7, 2021; May 7, 2021; September 7, 2021; January 7, 2022; May 7, 2022; September 7, 2022
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.
Award: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.
Eligibility & Guidelines: Here
Announcement Expires:  September 7, 2022


Title: Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Career Enhancement Award)
Announcement Number: PAR-19-238
Deadline: February 12, June 12, October 12
Purpose: This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial (DOC) research with a focus on behavioral and social sciences, and on genetics, genomics, bioinformatics and computational biology research. The intent of this program is to provide mid-career and senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field, in order to enrich their existing DOC research program; and (b) established investigators in other fields who seek training with DOC research investigators in order to facilitate the introduction of DOC research into an existing research program.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Award: Award budgets are composed of salary and other program-related expenses, as described below. A project period from 2.5 months to 12 months may be requested.
Eligibility & Guidelines: Here
Announcement Expires:  May 8, 2022


Training (K Announcements)

Title: Mentored Research Scientist Development Award (K01 Training Grant)
Announcement Number: PA-20-190
Deadline: February 12, June 12, October 12
Purpose: The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances..
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA.
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: May 8, 2023


Title: Mentored Quantitative Research Development Award (K25 Training Grant)
Announcement Number: PA-20-199
Deadline: March 12, July 12, November 12
Purpose: The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and “protected time” for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA (PA-20-197).
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: May 8, 2023


Title: Mentored Clinical Scientist Research Career Development Award (K08)
Announcement Number: PA-19-117
Deadline: February 12, June 12, October 12
Purpose: The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and “protected time” to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-116).
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: Mentored Patient-Oriented Research Career Development Award (K23)
Announcement Number: PA-19-119
Deadline: February 12, June 12, October 12
Purpose: The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-118).
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: Midcareer Investigator Award in Patient-Oriented Research (K24)
Announcement Number: PA-19-122
Deadline: February 12, June 12, October 12
Purpose: The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-121).
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00)
Announcement Number: PAR-19-144
Deadline: February 12, June 12, October 12
Purpose: This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19- 141).
The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.
Award: Award budgets are composed of salary and other program-related expenses.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2022


Title: NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00 Individual Predoctoral to Postdoctoral Transition Award)
Announcement Number: PAR-20-069
Deadline: February 12, June 12, October 12
Purpose: The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00) is to support outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences, over the transition from predoctoral to postdoctoral research training.. This phased award program will facilitate completion of graduate PhD or dual degree clinician scientist programs (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable achievement of an independent research faculty position and subsequent NIDCR career development and research project awards. This Funding Opportunity Announcement (FOA) does not allow prospective fellows to propose to lead an independent clinical trial, but does allow prospective fellows to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Award: For the F99 phase, award budgets are composed of stipends, tuition and fees, and institutional allowance, as described below.
For the K00 phase, award budgets are composed of salaries and fringe benefits, research and career development support, and indirect costs, as described below.
Eligibility & Guidelines: Here
Announcement Expires: January 8, 2023